Beida Weiming and Dakang Medical Announce Strategic Partnership to Jointly Operate Hemodialysis Centers Across Multiple Cities

On the afternoon of August 17, Beijing Peking University Weiming Biological Engineering Group Co., Ltd. (“Peking University Weiming”) and Beijing Dakang Medical Investment Co., Ltd. (“Dakang Medical”) held a signing ceremony for their strategic cooperation in nephrology and hemodialysis. Mr. Luo Deshun, Senior Vice President of Peking University Weiming, and Mr. Chen Shaobo, Chairman of Dakang Medical, jointly witnessed the signing ceremony and announced that the two parties would embark on strategic cooperation in the fields of nephrology and hemodialysis.

This collaboration will fully leverage the respective strengths of both parties. By capitalizing on Peking University Weiming’s robust capabilities in biomedicine, as well as its expertise in building bio-economy communities and the Health Internet of Things (IoHT), and combining these with Dakang Medical’s extensive experience in nephrology and the preparation, operation, and management of hemodialysis centers, the two parties will cooperate to operate hemodialysis centers in multiple cities across China. This partnership is poised to make a significant impact on China’s already booming hemodialysis market. Such full-industry-chain collaboration, spanning from manufacturers to hospitals, will further highlight the cost advantages and operational efficiency of both parties, consolidate their leading positions within their respective industries, and provide new insights for the development of China’s hemodialysis sector.and new models, bringing more professional care to patients with uremia,A Superior Medical Service Experience.

Peking University Weiming is one of the three major industrial groups under Peking University, dedicated to “building a bioeconomy system and creating a flagship enterprise for the bioeconomy.” It focuses on investments in six key sectors: biopharmaceuticals, bio-agriculture, bioenergy, bio-environmental protection, biological services, and intelligent biomanufacturing. Adhering to its corporate philosophy of “rejuvenating the nation through science and education, serving the country through industry, and strengthening the nation through health,” Peking University Weiming has made numerous pioneering and breakthrough contributions to the development of China’s bioindustry. After more than two decades of growth, it has initially established the world’s first bioeconomy system, the world’s first bioeconomy pilot zone, and the world’s first bioeconomy incubator, emerging as a global source of bioeconomic innovation. It stands as a flagship enterprise in China’s modern bioindustry and one of the Chinese corporate groups with the greatest potential for international competitiveness.

Dakang Medical is the first implementing entity of the independent hemodialysis pilot project launched by the National Health and Family Planning Commission. It operates multiple Bethune Hemodialysis Centers and stands as China’s leading professional healthcare service provider with the largest number of independent hemodialysis centers, the longest track record in operating chain centers, and the most extensive experience in planning, construction, and operational management. Through years of accumulation, Dakang Medical has pioneered an independent chain hemodialysis development model characterized by “unified management standards, unified medical standards, and unified service standards,” forming a comprehensive and effective solution set spanning from the preparation and construction of hemodialysis centers to their operational management. Currently, Dakang Medical is actively expanding its presence in China’s nephrology and hemodialysis markets.